I've re-read the preso today a few times re. asthma and considered the directors backgrounds (involved in biochemistry and molecular biology). The info on page 7 sticks out the most:
⊚ Asthma and related respiratory disease will be the third largest global therapeutic categories, with $41B - $46B in combined sales
⊚ As the industry looks to the future, this growing market represent an opportunity for manufacturers to introduce novel molecules, new combinations and innovative delivery devices to help better treat patients.
⊚ Most widely-used asthma medicines today employ a molecule that has long since lost patent protection, instead relying on unique, patented delivery devices
⊚ New first-in-class molecules could challenge top selling brands like Advair ($5B+ in sales) and Singulair (~$4B in sales)
SBN Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
